GleamWall
中文EN

VICP Vicapsys Life Sciences, Inc.

Pharmaceutical Preparations · OTC · SEC CIK 1468639 · Fiscal year ends 12/31

Financial factors as of 2024-09-30 (2024Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-24.8%
TTM EPS YoY0.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-904.2%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets3,053.8%
Debt / equity—
Current ratio0.03x
Interest coverage-62.88x

Cash quality & payout

Operating cash flow / net income0.09x
Accruals ratio-819.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2024Q32024-09-302024Q22024-06-302024Q12024-03-312023Q4*2023-12-312023Q32023-09-302023Q22023-06-302023Q12023-03-312022Q4*2022-12-31
Income statement
Revenue————————
R&D expense$3,746$10,000$344$0$3,267$2,000$10,000$0
SG&A expense$4,116$2,841$34,864$32,355$26,925$15,313$3,763$18,988
Operating income-$198,862-$181,841-$204,255-$527,207-$175,423-$135,693-$211,277-$492,605
Interest expense$36,645$8,250-$36,517$9,309$9,954———
Pretax income-$235,507-$190,091-$327,072-$594,803-$240,340-$135,693-$211,277-$492,605
Net income-$235,507-$190,091-$327,072-$594,803-$240,340-$135,693-$211,277-$492,605
EPS (basic)-0.01-0.01-0.01—-0.010.00-0.01—
EPS (diluted)-0.01-0.01-0.01—-0.010.00-0.01—
Weighted avg. shares (diluted)34.33M34.19M32.07M—34.41M35.31M34.59M—
Balance sheet
Cash & equivalents$89,569——$9,422$53,532$231,277$4,140$14,097
Current assets$89,569——$39,656$208,486$378,147$63,293$72,021
Total assets$89,569——$39,656$208,486$378,147$63,293$72,021
Current liabilities$2.74M$2.45M$2.26M$1.97M$1.54M$1.47M$1.20M$1.02M
Short-term debt—$12,546$12,546$18,712$36,789$54,230——
Total liabilities$2.74M——$1.97M$1.54M$1.47M$1.20M$1.02M
Shareholders' equity-$2.65M-$2.45M-$2.26M-$1.93M-$1.33M-$1.09M-$1.14M-$950,791
Shares outstanding32.37M32.07M32.07M32.07M32.07M31.19M31.19M31.19M
Cash flow statement
Operating cash flow-$40,431$6,166-$9,422-$82,054-$107,410-$218,103-$9,957$2,888
Financing cash flow$130,000——$37,944-$70,335——-$15,001
Stock-based compensation———$0$0$0$20,697$62,093

Free plan shows the latest 8 periods; Pro shows all 23 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.